Common Contracts
4 similar Employment Letter Agreement contracts by Icosavax, Inc.
ICOSAVAX, INC.Employment Letter Agreement • May 14th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of your position at Icosavax, Inc. (the “Company”), as previously set forth on that certain Consulting Agreement, dated September 1, 2018 (the “Prior Agreement”), by and between the Company and you (also referred herein as “Employee” and together, the “Parties”). Please note that this employment letter agreement (this “Agreement”) is contingent on the closing of the Transaction (the “Closing”), and shall become effective as of the Closing (the “Effective Date”). In the event the Closing does not occur on or before December 31, 2019, this Agreement shall have no force and effect and shall be null and void, and the Prior Agreement shall remain in effect. In consideration of the mutual promises herein contained, the Parties agree as follows:
ICOSAVAX, INC.Employment Letter Agreement • May 14th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of your position at Icosavax, Inc. (the “Company”), as previously set forth on that certain Consulting Agreement, dated January 1, 2018 (the “Prior Agreement”), by and among the Company, you and Palindrome Bioconsulting, LLC (also referred herein as “Employee” and together, the “Parties”). Please note that this employment letter agreement (this “Agreement”) is contingent on the closing of the Transaction (the “Closing”), and shall become effective as of the Closing (the “Effective Date”). In the event the Closing does not occur on or before December 31, 2019, this Agreement shall have no force and effect and shall be null and void, and the Prior Agreement shall remain in effect. In consideration of the mutual promises herein contained, the P
ICOSAVAX, INC.Employment Letter Agreement • May 14th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
In connection with the transactions contemplated by the Series A Preferred Stock Purchase Agreement, dated as of August 15, 2019, by and among the Company and the Purchasers named therein (the “Transaction”), we are amending and restating the terms of your position at Icosavax, Inc. (the “Company”), as previously set forth on that certain Consulting Agreement, dated January 1, 2018 (the “Prior Agreement”), by and between the Company and you (also referred herein as “Employee” and together, the “Parties”). Please note that this employment letter agreement (this “Agreement”) is contingent on the closing of the Transaction (the “Closing”), and shall become effective as of the Closing (the “Effective Date”). In the event the Closing does not occur on or before December 31, 2019, this Agreement shall have no force and effect and shall be null and void, and the Prior Agreement shall remain in effect. In consideration of the mutual promises herein contained, the Parties agree as follows:
ICOSAVAX, INC.Employment Letter Agreement • May 14th, 2021 • Icosavax, Inc. • Biological products, (no disgnostic substances) • Washington
We are amending and restating the terms of your position at Icosavax, Inc. (the “Company”), as previously set forth in that certain Employment Letter Agreement, dated October 30, 2019 (the “Prior Agreement”), by and between the Company and you (the “Employee”). In consideration of the mutual promises herein contained, the parties agree as follows:
